Drug prolongs life expectancy for lung cancer patients: study
The cancer drug Erbitux prolonged the lives of patients with advanced lung cancer by five weeks, according to a new clinical study described as an important gain for such individuals.”Patients with advanced NSCLC (non-small cell lung cancer) have limited treatment options and life expectancy is short, so the survival increase shown in this study is an important step for these patients,” said Robert Pirker of the Medical University of Vienna, a lead investigator in the study.
Lung cancer patients typically have a 30 percent chance of living a year and a one to two percent chance of surviving five years, Pirker explained Sunday at the 44th annual conference of the American College of Clinical Oncology.
This entry was posted on Monday, June 2nd, 2008 at 12:22 pm and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.